A venture capital firm invests in transformative mental health deep tech, including psychedelics and neurotechnology. The firm invests in Pre-Seed, Seed, and Series A companies, aiming to bridge the Series A funding gap and democratize access to frontier modalities at scale. Typical initial investments range from $250,000 to $2 million, with the possibility of follow-on funding. The firm is open to both leading and co-investing in deals, and may take board seats or observer roles on a case-by-case basis. It maintains a global investment scope and is not limited to opportunities within the U.S.
The firm focuses on transformative technologies that address mental health challenges. Areas of particular interest include psychedelic medicines, especially non-hallucinogenic neuroplastogens (notably NCEs), and short-duration psychedelic compounds aligned with the Spravato medical model. It also invests in digital therapeutics and neurotechnology designed for mental health applications. While the firm is open to early-phase companies, it has a preference for those with strong IP and patent portfolios. It looks for innovations that can make a significant impact on mental health treatments and patient outcomes and places a strong emphasis on ethical conduct.
The firm does not have strict requirements for founding teams. Its management team, composed of startup founders and operators, provides extensive support to portfolio companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment